Should You Buy Novo Nordisk Right Now?

Novo Nordisk (NVO) is facing divided Wall Street sentiment, with a recent stock decline reflecting market disappointment over Wegovy's weight loss market share loss to Eli Lilly's Zepbound, leading to a Morgan Stanley downgrade despite an HSBC upgrade. However, the company has several near-term catalysts that could drive a positive re-rating, including an anticipated FDA decision this year for its oral weight loss pill, mid-January completion of a Phase 3 trial for its next-generation weight loss drug CagriSema, and late 2025/early 2026 results from a Phase 3 Alzheimer's trial for semaglutide, offering significant speculative upside.

Analysis

Novo Nordisk (NVO) is currently experiencing bifurcated analyst sentiment, with Morgan Stanley downgrading to underweight due to disappointing U.S. prescription growth, while HSBC Holdings upgraded to buy, citing strong pipeline potential. This mixed view follows a perceived nearly 50% share drop, largely attributed to Wegovy's market share erosion by Eli Lilly's (LLY) Zepbound in the competitive weight loss market. This dynamic underscores the intense competition within the GLP-1 agonist space.

Despite recent market share challenges, NVO has several near-term catalysts that could drive a positive re-rating. The company anticipates an FDA decision this year for its oral weight loss pill (oral Wegovy), which has demonstrated potential superiority over Eli Lilly's candidate, orforglipron. Additionally, results from the Phase 3 REDEFINE 4 trial for its next-generation weight loss drug, CagriSema, against Eli Lilly's tirzepatide are expected by mid-January.

A longer-term catalyst involves Phase 3 trial results for semaglutide in Alzheimer's patients, aimed at slowing cognitive decline, with data anticipated in late 2025 or early 2026. However, previous efficacy data for CagriSema has disappointed, and a Novo Nordisk executive characterized the Alzheimer's trial as a "lottery," highlighting the inherent speculative nature and risks associated with these pipeline developments.

Key Decisions for Investors

• Investors should closely monitor the anticipated FDA decision for oral Wegovy this year and the mid-January completion of the CagriSema Phase 3 trial for potential stock re-rating.
• Given the 'speculative buy' tone and previous efficacy disappointments for CagriSema, a thorough risk-reward assessment is crucial, particularly concerning market share competition with Eli Lilly.
• For longer-term investors, the Alzheimer's trial results in late 2025/early 2026 present significant, albeit high-risk, upside potential, warranting attention despite the 'lottery' characterization.